A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...

But new research published in JAMA Pediatrics found distinct patterns of long COVID symptoms in young children. Researchers ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...